U.S. FDA approves Novartis therapy for prostate cancer

✔ Fact Checked by TDPel News Desk

By Lola Smith

Published: March 28, 2022 | 8:45 AM

The U.S. Food and Drug Administration approved Novartis AG’s (NOVN.S) therapy for the treatment of patients with a type of advanced prostate cancer that has spread to other parts of the body, the drugmaker said.

Novartis’ Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments.

The company bought the therapy as part of its $2.1 billion purchase of cancer drugmaker Endocyte in 2018.

Pluvicto is a precision treatment combining a targeting compound, or ligand, with a cancer-killing radioactive particle, Novartis said.

The company said it has submitted marketing authorization for Pluvicto to the European Medicines Agency and other health authorities.

Two late-stage studies evaluating Pluvicto in earlier lines of treatment for metastatic prostate cancer are underway, according to Novartis.

We are taking you to the next article automatically...You can cancel it below or click Load Now to read it now!

About Lola Smith

Lola Smith is a highly experienced writer and journalist with over 25 years of experience in the field. Her special interest lies in journalistic writeups, where she can utilize her skills and knowledge to bring important stories to the public eye. Lola’s dedication to her craft is unparalleled, and she writes with passion and precision, ensuring that her articles are informative, engaging, and thought-provoking. She lives in New York, USA.